Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Neuropace Inc (NPCE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: NPCE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 256.87% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 398.21M USD | Price to earnings Ratio - | 1Y Target Price 17.29 |
Price to earnings Ratio - | 1Y Target Price 17.29 | ||
Volume (30-day avg) 229453 | Beta 2.04 | 52 Weeks Range 5.45 - 15.77 | Updated Date 04/6/2025 |
52 Weeks Range 5.45 - 15.77 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -33.97% | Operating Margin (TTM) -17.02% |
Management Effectiveness
Return on Assets (TTM) -13.39% | Return on Equity (TTM) -189.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 418793389 | Price to Sales(TTM) 4.98 |
Enterprise Value 418793389 | Price to Sales(TTM) 4.98 | ||
Enterprise Value to Revenue 5.24 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 32560100 | Shares Floating 21126966 |
Shares Outstanding 32560100 | Shares Floating 21126966 | ||
Percent Insiders 3.58 | Percent Institutions 61.81 |
Analyst Ratings
Rating 4.83 | Target Price 16.17 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Neuropace Inc
Company Overview
History and Background
NeuroPace, Inc. was founded in 1997. The company focuses on developing and commercializing brain-responsive neuromodulation therapies for neurological disorders, particularly epilepsy. Its flagship product is the RNS System.
Core Business Areas
- RNS System: The core business involves the development, manufacturing, and commercialization of the RNS System, a closed-loop brain-responsive neurostimulation system for treating refractory epilepsy.
- Therapy Development: Research and development efforts focused on expanding the applications of brain-responsive neuromodulation to other neurological and psychiatric disorders.
Leadership and Structure
NeuroPace is led by a CEO and a management team overseeing various departments, including research and development, sales and marketing, clinical affairs, and regulatory affairs. The company has a board of directors responsible for corporate governance.
Top Products and Market Share
Key Offerings
- RNS System: The RNS System is the company's primary product. It is an implantable neurostimulator that monitors brain activity, detects abnormal electrical patterns, and delivers targeted electrical stimulation to disrupt seizures at their source. The market share of the RNS system is approximately 25% of the responsive neurostimulation market. Competitors include Medtronic (for DBS) and other surgical epilepsy treatments.
Market Dynamics
Industry Overview
The neuromodulation market is growing, driven by technological advancements and increasing demand for effective treatments for neurological disorders like epilepsy. The market includes neurostimulation devices, spinal cord stimulators, and deep brain stimulation systems.
Positioning
NeuroPace is positioned as a leader in brain-responsive neuromodulation for epilepsy. Its RNS System offers a unique closed-loop approach that distinguishes it from traditional open-loop neurostimulation devices.
Total Addressable Market (TAM)
The estimated TAM for epilepsy treatment is multi-billion USD annually. NeuroPace is positioned to capture a significant portion of this market through increased adoption of the RNS System, especially in patients with drug-resistant epilepsy.
Upturn SWOT Analysis
Strengths
- Proprietary brain-responsive technology
- Clinically proven efficacy in reducing seizure frequency
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited market penetration
- High cost of the RNS System
- Complex surgical procedure for implantation
- Dependence on a single core product
Opportunities
- Expansion of RNS System indications to other neurological disorders
- Increased adoption by epileptologists and neurosurgeons
- Strategic partnerships with healthcare providers and research institutions
- Development of next-generation neuromodulation technologies
Threats
- Competition from established neuromodulation companies
- Technological obsolescence
- Adverse regulatory changes
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- MDT
- ABMD
- LIVN
Competitive Landscape
NeuroPace has a competitive advantage in brain-responsive neuromodulation, but faces competition from larger companies like Medtronic that offer broader neurostimulation solutions.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: NeuroPace's historical growth has been driven by increasing adoption of the RNS System, particularly in refractory epilepsy patients.
Future Projections: Future growth is expected to be driven by continued market penetration, expansion of indications, and strategic partnerships.
Recent Initiatives: Recent initiatives include expanding the sales force, conducting clinical trials for new indications, and enhancing the RNS System's software capabilities.
Summary
NeuroPace is a promising company in the neuromodulation space with its unique brain-responsive technology. While it faces challenges related to market penetration and cost, its clinically proven efficacy and potential for expansion position it for future growth. The company needs to increase adoption among epileptologists, navigate reimbursement challenges, and watch out for competitors' neurostimulation technologies.
Similar Companies
LIVN
LivaNova PLC
LIVN
LivaNova PLC
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuropace Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 184 | Website https://www.neuropace.com |
Full time employees 184 | Website https://www.neuropace.com | ||
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.